ACSL4 and gastric cancer: HDAC inhibitors (HDACi) remodel lipid metabolism by upregulating key enzymes such as acyl-CoA synthetase long-chain family member 4 (ACSL4) and P450 oxidoreductase (POR), while downregulating solute carrier family 7 member 11 (SLC7A11), which triggers lipid peroxidation accumulation and ultimately induces ferroptosis, thus inhibiting GC progression [108].